September 2016—Mayo Clinic has launched a new type of blood test that will be used to predict adverse cardiovascular events in patients with progressing coronary artery disease. The test measures blood concentrations of plasma ceramides, a class of lipids that are highly linked to cardiovascular disease processes. Researchers say this test is especially useful for patients with CAD when it does not improve with treatment or for young patients with premature CAD.
The test will help clinicians identify at-risk individuals and is available to Mayo Clinic patients and health care providers worldwide through Mayo Medical Laboratories. MML collaborated on the test with Zora Biosciences Oy, a diagnostics discovery company based in Finland that specializes in cardiovascular disease.
The test also might be used to determine if treatment is necessary in people who are at intermediate risk via the risk calculator from the American College of Cardiology and the American Heart Association.
Mayo Clinic, 507-284-5005